drugset / Trial / NCT02998190

First-in-Human Single and Multiple Dose of EB8018

NCT02998190 ↗

Phase 1 Completed 60 enrolled Enterome Quotient Clinical · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety profile of single and multiple doses of EB8018 in healthy male subjects, to determine the pharmacokinetic profile of single and multiple doses of EB8018 in healthy male subjects and to assess preliminary effects of EB8018 on the healthy male gut microbiome.

Timeline

Start
2016-11
Primary completion
2017-04
Completion
2017-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Sibofimloc Small molecule — Oral

Indications

No indication recorded.